Literature DB >> 8210301

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

E M Hay1, P A Bacon, C Gordon, D A Isenberg, P Maddison, M L Snaith, D P Symmons, N Viner, A Zoma.   

Abstract

The British Isles Lupus Assessment Group (BILAG) index is a computerized index for measuring clinical disease activity in systemic lupus erythematosus (SLE), which was developed according to the principle of the physician's 'intention to treat'. The index allocates separate alphabetic scores to each of eight organ-based systems; a total score is not calculated. This study demonstrated good between-rater reliability for the BILAG index for each organ-based system. There was no evidence of bias between observers. The BILAG index had good overall sensitivity (87%) and specificity (99%) when compared with the 'gold standard' criterion (starting or increasing disease-modifying therapy). There were high positive predictive values overall (80%), and for each organ-based system, with the exception of the neurological system.

Entities:  

Mesh:

Year:  1993        PMID: 8210301

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  129 in total

Review 1.  The use of immunosuppressive and cytotoxic drugs in non-malignant disease.

Authors:  P A Brogan; M J Dillon
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

2.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

3.  Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes.

Authors:  Paul Eggleton; Lorna W Harries; Giada Alberigo; Paul Wordsworth; Nick Viner; Richard Haigh; Suzanne Donnelly; Hugh W Jones; Ian C Chikanza; Thomas W E O'Conner; Alasdair E R Thomson; Paul G Winyard
Journal:  J Clin Immunol       Date:  2010-06-09       Impact factor: 8.317

4.  Toward the development of criteria for global flares in juvenile systemic lupus erythematosus.

Authors:  Hermine I Brunner; Marisa S Klein-Gitelman; Gloria C Higgins; Sivia K Lapidus; Deborah M Levy; Anne Eberhard; Nora Singer; Judyann C Olson; Karen Onel; Marilynn Punaro; Laura Schanberg; Emily von Scheven; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

5.  Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus.

Authors:  Hermine I Brunner; Gloria C Higgins; Marisa S Klein-Gitelman; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Edward H Giannini
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

6.  Markers of childhood lupus nephritis indicating disease activity.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Dieter Haffner; Heiko Billing; Burkhard Tönshoff; Sophia Ross; Jörg Dötsch; Oliver Amon; Henry Fehrenbach; Christian Steuber; Antje Beissert; Josef Hager; Gottfried Wechselberger; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

7.  Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus.

Authors:  Elizabeth C Jury; Panagiotis S Kabouridis; Fabian Flores-Borja; Rizgar A Mageed; David A Isenberg
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus.

Authors:  M S Atta; K L Lim; D A Ala'deen; R J Powell; I Todd
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

9.  Belimumab in systemic lupus erythematosus: an update for clinicians.

Authors:  Susan S Kim; Kyriakos A Kirou; Doruk Erkan
Journal:  Ther Adv Chronic Dis       Date:  2012-01       Impact factor: 5.091

Review 10.  [Systemic lupus erythematosus. Target criteria for treatment].

Authors:  T Alexander; R Biesen; A Jacobi; B Hoyer; A Bruns; F Hiepe
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.